Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products
Abstract Gene and cell therapy research recently reached a fundamental milestone toward the goal to deliver new medicines for orphan diseases. In 2016, the European Commission granted market approval to GlaxoSmithKline (GSK) for ex vivo hematopoietic stem cell (HSC) gene therapy for the treatment of...
Saved in:
| Main Authors: | Alessandro Aiuti, Maria Grazia Roncarolo, Luigi Naldini |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2017-04-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201707573 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
by: Utpal P Davé, et al.
Published: (2009-05-01) -
The NeuroNEXT Gene Therapy Consortium: Designing and Advising on Quality Gene Therapy Trials in Rare and Ultra-rare Neurological Disorders
by: David Klements, MS, et al.
Published: (2025-07-01) -
Papillomavirus-like particles as vectors for ex vivo gene therapy of the skin
by: Francesco Diversi, et al.
Published: (2025-06-01) -
Cytomegalovirus infection and drug resistance emergence during letermovir salvage therapy in a pediatric SCID patient
by: Fien Horsten, et al.
Published: (2025-05-01) -
SCID/NOD mice model for 5-FU induced intestinal mucositis: Safety and effects of probiotics as therapy
by: Lawrence Huang, et al.
Published: (2019-06-01)